NCT03576755View on ClinicalTrials.gov

Spironolactone Therapy In Young Women With NASH

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 9, 2019

Primary Completion Date

July 5, 2023

Study Completion Date

July 5, 2023

Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
DRUG

Spironolactone 100mg

Spironolactone capsules will be prepared from USP grade powder at a dose of 100 mg.

DRUG

Placebo oral capsule

Matching placebo capsules of the same color, mass, and appearance to the spironolactone capsules will be filled using microcrystalline cellulose powder.

Trial Locations (1)

94143

University of California San Francisco, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER

NCT03576755 - Spironolactone Therapy In Young Women With NASH | Biotech Hunter | Biotech Hunter